Brief: Immix Biopharma Announces Patient Dosing In Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
13/12/2022 13:25
Dec 13 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES PATIENT DOSING IN ONGOING PHASE
1B/2A
IMX-110 MONOTHERAPY CLINICAL TRIAL
* IMMIX BIOPHARMA INC - IMX-110 CLINICAL TRIAL DATA EXPECTED
TO BE
RELEASED ON A ROLLING BASIS BEGINNING IN Q1 2023
* IMMIX BIOPHARMA INC - IN DECEMBER 2022, 15TH PATIENT WAS
DOSED
WITH IMX-110
Source text for Eikon: ID:nGNX57TBRW
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary